Press Release May 18, 2021

Vedere Bio II Launches with $77 Million Series A Financing

The Life Sciences team advised Vedere Bio II, Inc. on its $77 million Series A financing.

Vedere is developing next generation ocular gene therapies designed for vision restoration and preservation for patients with vision loss due to photoreceptor death.

Founded by the leadership and research team behind the former Vedere Bio, which was acquired by Novartis in September 2020, Vedere will leverage its new, proprietary, mutation agnostic optogenetics technology to improve upon current gene therapies by restoring functional vision to patients.

The financing was led by Octagon Capital, who was also joined by new investors Samsara BioCapital and Casdin Capital, and Vedere's founding investors, Atlas Venture, Mission BioCapital and the RD Fund, the venture arm of Foundation Fighting Blindness.

The Goodwin team was led by Kingsley Taft and Jake Hays.

For more details, read the press release and articles in Endpoints, Fierce Biotech, and BioSpace.